Abbvie Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis and inflammatory disorders.
Contineum Therapeutics Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, renal fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and scleroderma.
Haisco Pharmaceutical Group Co. Ltd. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, benign prostate hyperplasia, multiple sclerosis, neuronal injury and neuralgia.
AM Sciences Inc. has reported compounds acting as lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists described as potentially useful for the treatment of fibrosis.
A Contineum Therapeutics Inc. patent describes a crystalline form of lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of brain cancer, glioblastoma, idiopathic pulmonary fibrosis, inflammatory disorders, multiple sclerosis, neurodegeneration, neuropathic pain and scleroderma, among others.
Researchers from Contineum Therapeutics Inc. have presented preclinical data for the novel brain penetrant lysophosphatidic acid receptor 1 (LPAR1) antagonist, PIPE-791, being evaluated in models of neuropathic pain.
Lhotse Bio Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders, multiple sclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease [NAFLD]), osteoporosis, SARS-CoV-2 infection (COVID-19) and transplant rejection.
Lhotse Bio Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer and fibrosis, among others.
